- Home
- ANIX vs ADVM Comparison
ANIX vs ADVM Comparison
Compare ANIX & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ADVM
- Stock Information
- Founded
- ANIX 1982
- ADVM 2006
- Country
- ANIX United States
- ADVM United States
- Employees
- ANIX N/A
- ADVM N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- ADVM Health Care
- Exchange
- ANIX Nasdaq
- ADVM Nasdaq
- Market Cap
- ANIX 95.7M
- ADVM 94.6M
- IPO Year
- ANIX 1987
- ADVM 2014
- Fundamental
- Price
- ANIX $4.90
- ADVM $5.46
- Analyst Decision
- ANIX Strong Buy
- ADVM Strong Buy
- Analyst Count
- ANIX 3
- ADVM 4
- Target Price
- ANIX $9.00
- ADVM $19.75
- AVG Volume (30 Days)
- ANIX 216.1K
- ADVM 743.4K
- Earning Date
- ANIX 09-10-2025
- ADVM 11-03-2025
- Dividend Yield
- ANIX N/A
- ADVM N/A
- EPS Growth
- ANIX N/A
- ADVM N/A
- EPS
- ANIX N/A
- ADVM N/A
- Revenue
- ANIX N/A
- ADVM $1,000,000.00
- Revenue This Year
- ANIX N/A
- ADVM $1,449.40
- Revenue Next Year
- ANIX N/A
- ADVM N/A
- P/E Ratio
- ANIX N/A
- ADVM N/A
- Revenue Growth
- ANIX N/A
- ADVM N/A
- 52 Week Low
- ANIX $2.07
- ADVM $1.78
- 52 Week High
- ANIX $4.49
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- ANIX 81.97
- ADVM 71.48
- Support Level
- ANIX $3.21
- ADVM $4.72
- Resistance Level
- ANIX $3.44
- ADVM $5.58
- Average True Range (ATR)
- ANIX 0.21
- ADVM 0.63
- MACD
- ANIX 0.13
- ADVM 0.07
- Stochastic Oscillator
- ANIX 99.48
- ADVM 90.40
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.